Department of Surgery, Division of Otolaryngology, Yale University School of Medicine, New Haven, Connecticut, USA.
Otolaryngol Head Neck Surg. 2024 Feb;170(2):627-629. doi: 10.1002/ohn.558. Epub 2023 Oct 19.
With the American Joint Committee on Cancer (AJCC) 8th edition staging guidelines update, human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) is now staged separately from its HPV-negative counterpart, preventing meaningful comparison of cases staged with the 7th versus 8th edition criteria. Manual restaging is time-consuming and error-prone, hindering multiyear analyses for HPV+ OPSCC. We developed an automated computational tool for re-classifying HPV+ OPSCC pathological and clinical tumor staging from AJCC 7th to 8th edition. The tool is designed to handle large data sets, ensuring comprehensive and accurate analysis of historic HPV+ OPSCC data. Validated against institutional and National Cancer Database data sets, the algorithm achieved accuracies of 100% (95% confidence interval [CI] 98.8%-100%) and 93.4% (95% CI 93.1%-93.7%), successfully restaging 326/326 and 26,505/28,374 cases, respectively. With its open-source design, this computational tool can enhance future HPV+ OPSCC research and inspire similar tools for other cancer types and subsequent AJCC editions.
随着美国癌症联合委员会(AJCC)第 8 版分期指南的更新,人乳头瘤病毒阳性(HPV+)口咽鳞状细胞癌(OPSCC)现在与 HPV 阴性的 OPSCC 分开分期,从而阻止了第 7 版和第 8 版分期标准之间的有意义的病例比较。手动重新分期既耗时又容易出错,阻碍了 HPV+ OPSCC 的多年分析。我们开发了一种自动计算工具,用于将 HPV+ OPSCC 的病理和临床肿瘤分期从 AJCC 第 7 版重新分类到第 8 版。该工具旨在处理大型数据集,以确保对 HPV+ OPSCC 历史数据进行全面准确的分析。该算法经过机构和国家癌症数据库数据集验证,准确率达到 100%(95%置信区间[CI]98.8%-100%)和 93.4%(95% CI 93.1%-93.7%),分别成功重新分期了 326/326 例和 26,505/28,374 例。该计算工具具有开源设计,可以增强未来 HPV+ OPSCC 的研究,并为其他癌症类型和随后的 AJCC 版本激发类似的工具。